Align Technology Inc. (ALGN) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Align Technology Inc. (ALGN) advanced +0.06% to $153.71 as options desks priced 54% call premium vs. 46% put protection around the $151 max-pain magnet. Solid 67% profit margin (11% return on capital), mixed timing at 27x P/E—hold if owned, no rush to chase.
Align Technology’s third quarter results were shaped by a combination of resilient Clear Aligner demand and shifts in product mix, particularly toward lower-priced scanner configurations. Management cited record doctor p
Align Technology’s modeled fair value has been trimmed from US$199.21 to US$188.86, pointing to a more conservative price target in the latest update. This shift lines up with research that shows analysts reducing target
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Align Technology faces new catalysts, developments, and litigation progress that shift the investment landscape. I rate ALGN stock as Buy. Click to read my full update.
Align Technology, Inc. is downgraded from buy to hold with a $150 target price, reflecting limited upside. Read more on ALGN stock here.
Align Technology's Q3 earnings and revenues beat estimates on higher aligner shipments, but a lowered 2026 sales outlook weighs on shares.
Morgan Stanley analyst Erin Wright maintains Align Technology (NASDAQ:ALGN) with a Equal-Weight and lowers the price target from $188 to $175.
Moby summary of Align Technology, Inc.'s Q3 2026 earnings call
Record doctor submitters and aligner growth offset softer consumer spending headwinds.
Align Technology (NASDAQ:ALGN) reported third-quarter 2026 revenue of $1.015 billion, up 1.9% from a year earlier, as higher clear aligner volumes and international growth helped offset continued pressure in discretionar
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALGN. Explore sector supply chains on /butterfly.
Why ALGN Stock advanced +0.06% Today — RQD Quant Desk Flash. Solid 67% profit margin (11% return on capital), mixed timing at 27x P/E—hold if owned, no rush to chase.